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Abstract
Background: The optimal cancer treatment for an older population is largely unknown because
of the low numbers of elderly patients accrued into clinical trials. This project focuses on the
attitudes of the elderly about participation in clinical trials to determine if this is one of the barriers
to the involvement of this population in clinical trials.
Methods: The first phase of this study was a self-administered questionnaire mailed to 425 elderly
persons with cancer, selected from Princess Margaret Hospital oncology clinics. The second phase
consisted of individual semi-structured interviews with cancer patients to assess their attitudes
towards cancer, its management and enrolment into cancer clinical trials.
Results: Ninety-four patients responded to the survey giving a response rate of 22.1%. Three
quarters of respondents stated that they would be willing to participate in a clinical trial. The factors
that most influenced older patients' willingness to participate in a cancer study were
recommendations from a cancer doctor and the chance that the study treatment may help them
feel better. Seventeen survey responders participated in interviews. Common themes from these
interviews included patient-physician communication, the referral process, and the role of age in
cancer care decision-making.
Conclusion:  Most elderly people, who responded to this survey, are willing to consider
participation in cancer clinical trials however, elderly patients do not appear to actively seek clinical
trials and few were informed of the availability of clinical trials. Physician barriers and availability of
appropriate clinical trials may play a bigger role in preventing accrual of elderly cancer patients into
trials.
Background
Cancer is a disease of the elderly with 60 % of cancers
occurring in those over the age of 65 years [1]. As our pop-
ulation ages it will become increasingly critical to opti-
mise treatment in older patients to ensure both good
quality of life for this group and the best allocation of
medical resources. The treatment of cancer in the older
patient is challenging for a multitude of reasons. Firstly,
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care of the older patient is often complicated by comor-
bidities and other physiological factors, particularly dete-
riorating renal, bone marrow, and metabolic reserve [2].
This makes it extremely difficult to extrapolate informa-
tion concerning cancer care based on a younger popula-
tion to older patients. Secondly, there is a lack of
participation of elderly cancer patients in clinical trials
thus limiting the available information for physicians on
the appropriate management for this group [3-5]. Many
elderly patients with other co-morbid conditions may not
be accrued into clinical trials because of protocol eligibil-
ity requirements. Lastly, as with all clinicians, the cancer
specialist is frequently faced with situations where they
must balance their personal beliefs, professional values,
and knowledge of medicine with their patients' prefer-
ences and needs [6].
There have been many studies examining the lack of
accrual of elderly patients into clinical trials both in the
United States and in Canada. For instance, a study exam-
ining the data on over 16000 patients consecutively
enrolled between 1993 and 1996 in 164 studies con-
ducted by the Southwest Oncology Group (SWOG) in the
U.S. found that patients aged 65 years or older accounted
for only 25% of patients enrolled into the trials even
though they accounted for more than 60% of the U.S.
population with cancer [7]. A study in Canada demon-
strated similar results. While persons aged 65 or older
account for 58% of the Canadian population with cancer,
they were only enrolled into studies conducted by the
National Institute of Canada (NCIC) at a rate of 22% [8].
A recent review of the barriers to the recruitment of older
patients with cancer onto clinical trials suggested that age
continues to be a significant barrier to recruitment [9]. It
appears that physician's perceptions of the elderly, strict
protocol eligibility criteria, and restrictions on enrolling
patients with comorbid conditions may play the biggest
roles in preventing the accrual of older patients. Unfortu-
nately, although physician barriers, protocol barriers and
logistic barriers have been examined, there is a lack of
research investigating the older patient's attitude towards
clinical trials.
In order to gain a better understanding of possible causes
for the low accrual rate of older patients with cancer into
clinical trials the patient's perspective must be explored.
This study addresses the understanding and the attitudes
of the elderly towards enrolment into cancer clinical trials.
We have attempted to determine whether patient's aware-
ness and understanding of clinical trials, play a role in the
low accrual rate of elderly patients into cancer clinical tri-
als.
Methods
This project was performed in two phases.
Phase 1: Mailed survey
An invitation to participate in a self-administered ques-
tionnaire to identify and understand attitudes of the eld-
erly towards enrolment into cancer clinical trials was
mailed to 425 elderly persons with cancer. All patients
aged 70 and older who were seen at Princess Margaret
Hospital (PMH) oncology follow-up GI, lung and breast
clinics in April 2003 were invited to participate. One hun-
dred and fifty four peoplestated willingness to participate
and they were subsequently sent the questionnaire.
Although patients were recruited mainly from GI, breast
and lung clinics, patients from ambulatory clinics of other
tumor types were also approached. Also, patients with two
primary tumors were eligible and thus additional types of
cancers could be represented. There were no requirements
for active treatment or previous or ongoing clinical trial
participation. Participants had to have a life expectancy of
more than 12 weeks and to be able to read English.
Mailed reminders were sent at two and four weeks to max-
imise the survey response rate. The survey was completed
anonymously and participants were instructed to avoid
including their name or any other unique information on
the survey. To encourage response, a stamped, addressed
envelope and a brief letter describing the goals of the sur-
vey were included with every survey package. Participants
were also asked to complete and return an addressed post-
card if they were interested in participating in a one-on-
one interview at a later date.
By completing an extensive literature review to identify
barriers to cancer care (including enrolment in clinical tri-
als) for older patients, we composed a comprehensive sur-
vey consisting of a large number of items. Using a
modified Delphi technique, 4 investigators reduced the
list to a final group of questions felt to be most crucial to
identifying important issues for this patient population.
Prior to administration, the survey was pilot-tested with a
group of 5 elderly people to ensure that the survey was
clear and had appropriate face validity.
Data collection and analysis
Two members of the research team independently entered
the results of the survey into a database. Summary statis-
tics such as the median, percentage and frequency were
used to describe the respondents. Three potential predic-
tor variables, age, self-reported health status and whether
the patient believed they were cured of cancer or not, were
investigated for potential association with willingness to
participate in and factors affecting decision to participate
in clinical trials. To increase statistical power, categoriza-
tion of patients into two groups was performed for age (<
75 versus ≥ 75) and health status (excellent/good versus
poor/marginal/average). Similarly, level of agreement to
attitudes towards clinical trial statements was dichot-BMC Cancer 2006, 6:34 http://www.biomedcentral.com/1471-2407/6/34
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omized (strongly agree/agree versus strongly disagree/dis-
agree/neither disagree nor agree). Potential associations
were investigated using the chi-square test. All tests were
two-sided and p-values of 0.05 or less were considered sta-
tistically significant with no adjustment to the p-value
performed for multiple testing.
Phase 2: One-on-one semi-structured interviews
Study design
One-hour semi-structured interviews were completed
with those survey respondents who expressed interest in
this phase. This interview was conducted to further
explore their attitudes about cancer, cancer therapy, and
participation in clinical trials. A research coordinator with
extensive interview experience conducted the interview.
All participants received a stipend of $30 to compensate
for transportation and parking costs. Participants were
encouraged to speak feely, to raise issues that were impor-
tant to them and to support their responses with exam-
ples. Domains of inquiry were identified from discussion
among the authors (CAT, KC, LLS, SES) after review of the
results of the survey. The interview tapes were transcribed
verbatim and assigned a unique identifier for each partic-
ipant.
Analysis of interviews
Grounded theory was used to analyse the data from the
interviews by generating categories and themes [10]. The
analysis was initiated after the first interview to allow
emerging themes to be explored in subsequent interviews.
Sampling of participants continued until saturation was
achieved and no new themes were identified. Two investi-
gators, who were blinded to the identity of the participant,
independently coded the data to increase reliability. After
the transcripts were checked for accuracy the tapes were
destroyed.
Ethics
Patients were informed that they could refuse to partici-
pate at any time and that this would not impact on their
future care. Consent to participate in Phase 1 of the study
was implied by return of the postcard and completion of
survey. Participants were asked to complete a consent
form prior to the interview. Data did not include any
unique identifiers and none of the clinicians involved in
the care of the patients had access to this data. Ethics
approval was obtained from the University Health Net-
work and the University of Toronto.
Results
Phase 1: Self-administered questionnaire mailed to elderly 
persons with cancer
Baseline demographics
Ninety-four questionnaires were returned resulting in a
response rate of 61.4% (considering those that had origi-
nally agreed to participate) and 22.1% (considering the
original cohort who were invited to participate). The
demographics of the responders can be found in Table 1.
Over 80% of responders were between the ages of 70 and
79, approximately half were female and most responders
were living with a significant other. Over 50% of respond-
ents rated their health as good or excellent, with only 2%
Table 1: Participant demographics of mailed survey (n = 94)
Variable # respondents 
(% respondents)
Age
70–74 46 (49)
75–79 33 (35)
80–84 14 (15)
85–90 1 (1)
> 90 0 (0)
Gender:
NA 1 (1)
Male 51 (54)
Female 42 (45)
Living situation*
By yourself? 29 (31)
With spouse/significant other? 64 (68)
In a retirement home? 2 (2)
With children? 2 (2)
With friends? 0 (0)
In a nursing home? 0 (0)
Current health status?
NA 3 (3)
Poor 2 (2)
Marginal 13 (14)
Average 28 (30)
Good 40 (43)
Excellent 8 (9)
Type of cancer
Skin (not melanoma) 13 (14)
Melanoma 4 (4)
Lung 5 (5)
Breast 17 (18)
Prostate 19 (20)
Colon/rectum 27 (29)
Lymphoma 8 (9)
Other 29 (31)
Median (Range) Age at diagnosis (n = 91) 68 (41–81)
To the best of your knowledge, are you considered cured of cancer?
NA 3 (3)
Yes 31 (33)
No, but I am currently receiving treatment 27 (29)
No, but I was previously treated 20 (21)
No, I have never had any treatment 2 (2)
Do not know 11 (12)
* Multiple answers were possibleBMC Cancer 2006, 6:34 http://www.biomedcentral.com/1471-2407/6/34
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feeling that their health was poor. When asked about clin-
ical trials (table 2), most patients (70%) responded that
they had never participated in a clinical trial and only 3%
had ever sought information themselves about a clinical
trial. Most elderly patients with cancer felt that the two
most important treatment decision makers were them-
selves and their cancer or family doctor.
Attitudes towards clinical trial participation
Patients were asked three questions regarding their atti-
tudes towards participating in a clinical trial (Table 3).
About three quarters of patients would participate in clin-
ical trials to prevent or screen for cancer, just over half
would participate in clinical trials comparing a new drug
to a 'standard' drug, and 70% would participate in clinical
trials to test a new drug when there is no 'standard' drug
available. The only statistical significant predictor of
whether the patient would enrol in a clinical trial was
whether the patient believed they were cured as a predic-
tor of enrolment in a screening or prevention trial. Those
patients who believed they were cured indicated they were
less likely (62% versus 88%) to participate (p-value =
0.009).
Reasons to participate in a clinical trial
Respondents were asked about the reasons for participat-
ing in a hypothetical clinical trial (Table 4). The three
highest-ranking answers were a recommendation from
the cancer doctor, a chance that the patient may feel better
because of the treatment and a chance that this study may
help other cancer patients in the future. Interestingly, the
chance that the patient may live longer was rated lower
than the previously mentioned items, as only about 90%
agreed that an increased life span would affect their deci-
sion to participate. Recommendation from the family
doctor was felt to be important for decision making for
about 80% of responders and recommendations from
family/friends ranked last with less than 60% of respond-
ers feeling it was important. There was no significant dif-
ference in results based on age or health status. However,
patients who were not cured felt that the chance that they
may live longer was an important decision maker for
them (p-value = 0.012).
Reasons to decline participate in a clinical trial
Respondents were asked about factors that would affect
their decision not to participate in a clinical trial (Table 5).
The two highest ranking reasons not to participate in a
clinical trial were a recommendation from the cancer doc-
tor against participating and concerns about whether or
not the new treatment works. None of the answers dif-
fered significantly based on their age group, their health
status or whether or not the felt they had been cured of the
cancer. Recommendations from family, friends, or the
family physician would not have a significant impact on
the decision to enter a clinical trial. Similarly, age was not
seen as a reason for not participating in a clinical trial. No
statistically significant associations between age, health
status or perceived curative status was observed with any
factor.
Phase 2: Semi-structured one-on-one interviews with older 
cancer patients
Seventeen survey respondents agreed to participate in
interviews. Baseline demographics can be found in table
6. Most respondents were between the ages of 70 and 74,
with only one older than 85 years. More than half of the
respondents were male, most lived on their own at home,
many had completed post-secondary education and the
most common tumor type was colorectal cancer. Most
patients rated their health status as above average. Several
themes were identified around the attitudes that the
patients had towards cancer care and clinical trials includ-
ing; patient-physician communication, the referral proc-
ess, consent to clinical trial participation, the
randomization process and the role of age in cancer care
decision making.
Patient-physician communication
In all areas of medicine it is essential to have good com-
munication between the patient and the physician. Most
participants felt that the initial communication regarding
diagnosis was well done and although over half were
alone when they received news of their diagnosis, most
felt they would not have preferred to have someone there
with them at this moment. Patients stated that the most
important factor in feeling comfortable, while getting the
Table 2: Clinical trial demographics from mail survey
Clinical trial demographics # respondents 
(% respondents)
Participation in a cancer clinical trial
Yes 22 (23)
No 70 (74)
NA 2 (2)
Invited to participate in a cancer clinical trial n = 69:
Yes 13 (19)
No 56 (81)
Sought information about a cancer clinical trial n = 67
Yes 2 (3)
No 65 (97)
Participants in decision making
Yourself 73 (78)
Family 42 (45)
Friends 4 (4)
Your cancer/family doctor 81 (86)
Others 6 (6)BMC Cancer 2006, 6:34 http://www.biomedcentral.com/1471-2407/6/34
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initial diagnosis, was confidence in the physician giving
the news. One responder stated; "I think the key is that he
was young, vigorous man, who communicates very well
and is able to tell the patient exactly what the score is in
every respect, the techniques involved in surgery, the
chances of success or otherwise, and as I've said, he instils
confidence in the patient..."
Twelve participants felt they were happy to have had
someone accompany them when discussing cancer man-
agement options as this person was able to ask more ques-
tions and listen to information as well as to lend support.
All participants felt they had made final decisions regard-
ing cancer care themselves based on recommendations
from the cancer specialist. However, the treating physi-
cians heavily influenced some participants' treatment
decisions. One responder stated; "I would choose what-
ever had been recommended to me by the doctor or doc-
tors...I think that applies to pretty well everything..."
The referral process
Almost all respondents expressed a desire that the time to
removal of the primary tumour be as quick as possible if
this was an option in their treatment plan. According to
the patients waiting times ranged from 1 to 4 weeks from
diagnosis to surgery or referral to a radiation or medical
oncologist. None of the respondents felt that they had
waited an unacceptable amount of time but almost all
expressed a desire to be treated quickly.
Consent to clinical trial participation
There appeared to be some misunderstandings about clin-
ical trials and what participation would entail. For exam-
ple, many participants felt that the treating physician
should decide which treatment was better for them in a
clinical trial and that the patient should then receive that
arm. One patient stated he had never heard the expression
"clinical trial". Only 2 patients had been approached to
participate in a clinical trial excluding our study. Most
interview respondents felt they would be happy to con-
sider participating in a clinical trial if there was one avail-
able for their particular situation. None of the 15 patients
who had not been approached about a clinical trial were
aware of any information about clinical trials available
from their physician or another source. When asked about
the best way to communicate information about clinical
trials to elderly patients with cancer, many respondents
felt that using a newsletter sent to patients would be
appropriate. Some also felt that this information should
come from the treating physician. One patient stated,
"maybe if there was a newsletter type thing sent to doctors
that could be put in their office, detailing some of the ben-
efits of this, it might help generally to get people thinking
in the right direction."
The role of patient age in cancer care decision-making
All respondents felt that age should not be a factor if there
was no limitation on the amount of resources available.
One respondent stated: "You could have a much younger
person in poor health and you could have an older person
in good health, it (treatment) should depend on each par-
ticular individual not their age." If resources were limited
some felt that age should be taken into account. One
responder felt the decision not to perform surgery had
been based on his advanced age but at the same time was
glad that he did not go through an invasive procedure.
Table 3: Clinical trial participationNumber (%) of patients who agree/strongly agree to survey questions grouped by demographic 
characteristics of interest
Age Health Status Cancer Status
Question n/N (%) < 75 n/N (%) ≥ 75 p-value n/N (%) Good/Excellent n/N 
(%) Poor/Marginal/Ave
p-value n/N (%) Cured n/N (%) 
Not Cured
p-value
1) I would participate in 
'clinical trials' that study 
ways to prevent or screen 
for cancer
34/44 (77) 35/46 (76) 36/47 (77) 30/40 (75) 18/29 (62) 42/48 (88)
0.89 0.86 0.009
2) I would participate in a 
'clinical trial' to compare a 
new drug to the old 
"standard" drug
24/43 (56) 21/46 (46) 24/47 (51) 20/39 (51) 13/30 (43) 25/47 (53)
0.34 0.98 0.40
3) I would participate in a 
clinical trial to test a new 
drug when there is no 
"standard" drug available
34/45 (76) 30/47 (64) 32/47 (68) 29/42 (69) 18/30 (60) 37/49 (76)
0.22 0.92 0.15BMC Cancer 2006, 6:34 http://www.biomedcentral.com/1471-2407/6/34
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Discussion
Although there have been studies looking at the patient's
perspective regarding their cancer and treatment, there is
a paucity of information about how elderly patients feel
about clinical trials. As well, much of the available
research evaluates the patient's attitude towards the
screening of different types of cancer and not at their over-
all treatment. The elderly population experiences different
care from their younger counterparts as they are treated
less aggressively and enrolled in clinical trials less often.
The lack of data on the management of elderly patients
with cancer and their risk of adverse events with therapy
make management decisions difficult. Having the general
knowledge of the patient's beliefs may help to guide the
clinician regarding the best management approach.
This study takes an in-depth look at the attitudes of elderly
patients with cancer towards their disease and clinical tri-
als in cancer care. Two different methods were used to
address these issues; a mail out survey and one-on-one
interviews. Interestingly, the cancer specialist continues to
be a very important figure when deciding to participate in
a clinical trial. Surprisingly, the chance of increased sur-
vival was less important than the chance for better quality
of life when ranking reasons to participate in a clinical
trial. The influence of family and friends did not appear to
be very important in making decisions about participa-
tion in a clinical trial. Patients who were alone when they
met with their physicians at the time of their diagnosis felt
they did not need other family or friends there and relied
more on the physician's opinion.
There have been a few other studies looking at elderly can-
cer patient's attitudes towards cancer care [11-16]. Most
studies demonstrated that elderly patients had very simi-
lar views as their younger counterparts concerning issues
of cancer screening and cancer care. A study by Yellen et
al. looked at age and clinical decision-making in oncology
patients using clinical vignettes in an interview situation.
They found that older patients were as likely as their
younger counterparts to agree to chemotherapy for both
curative and control purposes, yet the older patients were
less willing to accept a more toxic treatment for an
increase in survival [17]. This is in keeping to the trends
we observed, showing that older patients placed slightly
less importance on the chance of living longer as a reason
to participate in a clinical trial. A much higher proportion
of those who stated they had not been cured of their dis-
Table 4: What factors are important in your decision to participate in a clinical trialNumber (%) of patients who agree/strongly agree 
to survey questions grouped by demographic characteristics of interest
Age Health Status Cancer Status
Question n/N (%) < 75 n/N (%) ≥ 75 p-value n/N (%) Good/Excellent n/N (%) 
Poor/Marginal/Ave
p-value n/N (%) Cured n/N (%) 
Not Cured
p-value
Recommendation from 
cancer doctor to 
participate
45/46 (98) 44/47 (94) 45/47 (96) 41/43 (95) 30/31 (97) 46/49 (94)
0.32 0.93 0.56
Recommendation from 
the family doctor to 
participate
36/46 (78) 40/46 (87) 38/47 (81) 35/42 (83) 25/31 (81) 39/48 (81)
0.27 0.76 0.95
Recommendation from 
family/friends to 
participate
26/46 (57) 26/45 (58) 24/49 (49) 23/39 (59) 17/31 (55) 28/47 (60)
0.90 0.35 0.68
The chance that you 
may live longer because 
of the treatment
43/46 (93) 40/46 (87) 41/47 (87) 39/42 (93) 24/31 (77) 46/48 (96)
0.29 0.38 0.012
The chance that you 
may feel better because 
of the treatment
44/46 (96) 44/46 (96) 45/47 (96) 40/42 (95) 30/31 (97) 45/48 (94)
1.00 0.91 0.55
The chance that this 
study may help other 
cancer patients in the 
future
44/45 (98) 43/46 (93) 44/46 (96) 40/42 (95) 30/31 (97) 44/47 (94)
0.32 0.93 0.54
Your age 31/44 (70) 28/46 (61) 29/45 (64) 28/42 (67) 20/30 (67) 29/47 (62)
0.34 0.83 0.66BMC Cancer 2006, 6:34 http://www.biomedcentral.com/1471-2407/6/34
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ease felt that the increased chance of survival was a very
important factor when making a decision to participate in
a clinical trial. We might hypothesize that those not cured
of their disease feel much more vulnerable with regards to
their own mortality and therefore would place more value
on any extra survival time, regardless of quality of life.
There has been one study examining how often elderly
breast cancer patients were offered clinical trials and their
attitudes towards them [18]. They found that sixty-eight
percent of younger stage II patients were offered a trial
compared with 34% of the older patients and of those
offered a trial, there was no significant difference in partic-
ipation between younger (56%) and older (50%)
patients. These trends were seen with our patient popula-
tion as well where few older patients had been offered a
clinical trial but the majority would be willing to partici-
pate in one.
Although this study draws attention to many important
points regarding the attitudes of the elderly patients with
respect to care of their cancer and clinical trial participa-
tion, there are a few limitations to this study. Our
response rate, was lower than we would have preferred
but our results were based on almost 100 elderly patients
representing one of the largest series of elderly cancer
patient surveys. It was our intention to target a well elderly
population to compare their responses with those from
patients with cancer. However, this was difficult due to the
lack of healthy control participants in the hospital and the
reluctance of the ethics review board to approve the target-
ing of a random external population. This low response
rate does present the potential for response bias. It is pos-
sible that the patients who agreed to participate in this
survey are also the ones that would be more inclined to
participate in clinical trials by their very nature. This may
make it difficult to extrapolate these results to the general
Table 5: What factors are important in your decision NOT to participate in a clinical trialNumber (%) of patients who agree/strongly 
agree to survey questions grouped by demographic characteristics of interest
Age Health Status Cancer Status
Question n/N (%) <75 n/N (%) ≥ 75 p-value n/N (%) Good/Excellent n/N (%) 
Poor/Marginal/Ave
p-value p-value
Recommendation from 
cancer doctor against 
participating
41/44 (93) 44/46 (96) 43/46 (93) 39/41 (95) 28/30 (93) 44/47 (94)
0.61 0.74 0.96
Your cancer doctor did not 
give you any advice about 
participating
34/42 (81) 38/45 (84) 34/44 (77) 35/40 (88) 23/28 (82) 37/46 (80)
0.67 0.22 0.86
Recommendation from 
your family doctor against 
participating
34/44 (77) 38/46 (83) 39/47 (83) 30/40 (75) 25/30 (83) 35/47 (74)
0.53 0.36 0.36
Your family doctor did not 
give you any advice about 
participating
22/43 (51) 28/45 (62) 24/45 (53) 24/40 (60) 16/28 (57) 25/47 (53)
0.30 0.54 0.74
Recommendations from 
your family and friends 
against participating
17/44 (39) 22/45 (49) 19/47 (40) 17/39 (35) 12/30 (40) 20/46 (43)
0.33 0.77 0.76
Your age 27/43 (63) 26/46 (57) 26/46 (57) 25/40 (63) 16/29 (55) 27/47 (57)
0.55 0.57 0.85
You have other health 
problems that make you 
feel too weak to participate
34/44 (77) 32/43 (74) 31/44 (70) 32/40 (80) 20/29 (69) 35/46 (76)
0.76 0.31 0.50
You have concerns about 
whether or not the new 
treatment works
41/44 (93) 40/46 (87) 40/46 (87) 38/41 (93) 27/30 (90) 41/47 (87)
0.33 0.38 0.71
You are afraid of possible 
side effects from the new 
treatment
33/44 (75) 40/46 (87) 34/46 (74) 36/41 (88) 22/30 (73) 38/47 (81)
0.15 0.10 0.44BMC Cancer 2006, 6:34 http://www.biomedcentral.com/1471-2407/6/34
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elderly population who may have a different view on clin-
ical trials. This study however, is still the largest cohort of
elderly cancer patients to be asked about clinical trials and
the results are interesting. Clearly more research will need
to be done on a larger population in the future.
One of the strengths of this study was the addition of indi-
vidual interviews to explore patient's perceptions of par-
ticipation in clinical trials. When performing qualitative
research such as the interpretation of individual inter-
views, efforts must be made to establish methodological
rigour and to avoid potential bias. Our team tried to min-
imize this by having more than one member independ-
ently analyze the data and develop the framework of
themes that arose from the results.
Other factors may play a role in affecting the accrual of
elderly patients onto clinical trials including the higher
prevalence of co-morbid conditions in the elderly which
in some instances may make them ineligible for studies
and at times logistic problems such as more difficulty
traveling to centres where clinical trials are being per-
formed. Our group did evaluate the referral patterns of
Ontario primary care physicians and found that although
86% of respondents would refer most older patients with
early-stage, potentially curable cancers to oncologists,
only 65% would refer those with advanced-stage, poten-
tially incurable cancers [18]. This may influence the type
of patients recruited to this study as some elderly patients
with cancer are not being referred to a cancer centre and
therefore do not have the opportunity to consider a clini-
cal trial.
It would appear that most older patients with cancer, who
responded to this survey, would willingly consider partic-
ipation in a clinical trial. However few older cancer
patients were informed of the availability of clinical trials
nor were they active in seeking the availability of clinical
trials. This may in part be due to the lack of knowledge in
this population concerning clinical trials in general. Phy-
sician barriers may play a bigger role in preventing accrual
of elderly cancer patients onto trials.
Conclusion
Most elderly people, who responded to this survey, are
willing to consider participation in cancer clinical trials
however, elderly patients do not appear to actively seek
clinical trials and few were informed of the availability of
clinical trials. Physician barriers and availability of appro-
priate clinical trials may play a bigger role in preventing
accrual of elderly cancer patients into trials.
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Table 6: Participant demographics of one-on-one interview 
participants (n = 17)
Variable # respondents 
(% respondents)
Age # respondents 
(% respondents)
70–74 11 (65)
75–79 4 (23)
80–84 1 (6)
85–90 1 (6)
> 90 0 (0)
Gender:
Male 9 (53)
Female 8 (47)
Education Level
Completed post secondary education 4 (23)
Completed High School 8 (47)
Completed Primary School 5 (30)
Participant's perception of health status
Poor 0
Marginal 1 (6)
Average 6 (35)
Good 4 (24)
Excellent 6 (35)
Living situation*
By yourself? 11 (65)
With spouse/significant other? 6 (35)
In a retirement home? 2 (12)
With children? 2 (12)
With friends? 0 (0)
In a nursing home? 0 (0)
Type of cancer
Skin (not melanoma) 2 (12)
Melanoma 1 (6)
Lung 1 (6)
Breast 2 (12)
Prostate 3 (17)
Colon/rectum 6 (35)
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